Home » Stocks » Marker Therapeutics

Marker Therapeutics, Inc. (MRKR)

Stock Price: $1.91 USD 0.02 (1.06%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $1.94 +0.03 (1.57%) Aug 13, 5:48 PM

Stock Price Chart

Key Info

Market Cap 89.04M
Revenue (ttm) 679,979
Net Income (ttm) -23.37M
Shares Out 46.53M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $1.91
Previous Close $1.89
Change ($) 0.02
Change (%) 1.06%
Day's Open 1.93
Day's Range 1.89 - 1.99
Day's Volume 189,267
52-Week Range 1.33 - 6.54

More Stats

Market Cap 89.04M
Enterprise Value 66.40M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.53M
Float 26.37M
EPS (basic) -0.51
EPS (diluted) -0.51
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.06M
Short Ratio 16.13
Short % of Float 15.00%
Beta 1.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 130.94
PB Ratio 2.55
Revenue 679,979
Operating Income -24.02M
Net Income -23.37M
Free Cash Flow -22.62M
Net Cash 22.64M
Net Cash / Share 0.49
Gross Margin -1,845.88%
Operating Margin -3,532.16%
Profit Margin -3,436.30%
FCF Margin -3,327.17%
ROA -29.00%
ROE -54.39%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.50*
(187.96% upside)
Low
2.50
Current: $1.91
High
8.00
Target: 5.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.210.210.18-----
Revenue Growth3.5%12.53%------
Gross Profit0.210.210.18-----
Operating Income-22.53-148-11.48-8.49-6.16-3.37-2.66-5.48
Net Income-21.43-148-10.98-2.46-34.07-30.88-5.53-6.17
Shares Outstanding45.5919.099.456.893.661.290.090.05
Earnings Per Share-0.47-7.75-1.16-0.72-9.30-24.00-58.44-113.05
Operating Cash Flow-18.28-14.48-8.44-6.51-4.34-2.19-0.69-1.59
Capital Expenditures-0.37-0.15------
Free Cash Flow-18.66-14.63-8.44-6.51-4.34-2.19-0.69-1.59
Cash & Equivalents43.9061.755.137.856.580.140.050.03
Total Debt0.48--0.010.050.053.481.55
Net Cash / Debt43.4261.755.137.856.520.09-3.43-1.52
Assets46.3662.145.187.926.650.220.080.09
Liabilities2.272.801.521.7428.011.258.856.13
Book Value44.0959.343.666.18-21.36-1.02-8.77-6.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Marker Therapeutics, Inc.
Country United States
Employees 28
CEO Peter L. Hoang

Stock Information

Ticker Symbol MRKR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRKR

Description

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.